SecBot SecBot
SECBOTREPLAY Home › Report › IMTX

IMTX · Immatics announced that four of its abstracts have been accepted for…

https://immatics.com/ · PRESS-RELEASE filed Apr 21, 2026 at 10:26 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 21, 2026 at 10:26 ET

Immatics announced that four of its abstracts have been accepted for oral presentation at the 2026 ASCO Annual Meeting, featuring clinical data from its PRAME-targeted cell therapies (anzu-cel, IMA203CD8) and MAGEA4/8 bispecific (IMA401) across multiple solid tumors. The presentations include updated Phase 1b and Phase 1a/1b data in melanoma, gynecologic cancers, synovial sarcoma, and first-in-human results for IMA401. This visibility at a top oncology conference highlights clinical progress in its core pipeline programs.

  • Four abstracts accepted for oral presentation at ASCO 2026, a high-impact oncology conference
  • Data includes updated Phase 1b results for anzu-cel in advanced melanoma and Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
  • First-in-human results for IMA401, a MAGEA4/8 bispecific, to be presented across multiple solid tumors
  • Presentations span melanoma, gynecologic cancers, and synovial sarcoma, demonstrating broad applicability of PRAME-targeted therapies

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access